ADHD in treatment seeking patients with a substance use disorder

van de Glind, G.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Funding resources and conflict of interest statements

Funding resources

The ICASA Foundation (www.adhdandsubstanceabuse.org) developed the IASP study, and arranged with its participating institutes that each of these institutes would seek funding for their regional process and data sampling efforts. The ICASA Network sought funding for the central organization costs. These central costs included:
- Organizing meetings for the network;
- Site visits for training and monitoring (The first author (VdG G) visited all of the institutes at least once, the European institutes were visited twice);
- Building a data base fit for remote data storage at the University of Amsterdam;
- Obtaining the right for use of the CAADID interview;
- Translating the instruments in the necessary languages;
- Cleaning the data;
- Analysing the study results and coordinating publishing;

In the period of development of the study the ICASA network received unrestricted grants from the following pharmaceutical companies: Janssen Cilag, Eli Lilly & Company, Shire. Since the ICASA Network is a formal foundation (September 2010) it operates independent from pharmaceutical funding. Since then funding was obtained via the following sources:
- Participating institutes;
- The Noaber Foundation; The Waterloo Foundation, The Augeo Foundation.

The local institutes report the following funding sources:

*The Netherlands, Amsterdam*: no external funding was obtained. The participating institute, Arkin, paid for the costs involved, and used funding from *Fonds NutsOhra* for this project.

*Norway, Bergen Clinics Foundation*: Main external funding has been the Regional research council for addiction in West Norway (Regionalt kompetansesenter for ruslimmelforskning i Helse Vest (KORFOR), funding a 50 % position. The remaining resources, with staff and infrastructure, has been from the Bergen Clinics Foundation.
Belgium: Funding of the IASP-project in Belgium: private funding.


Spain, Barcelona: Financial support was received from Plan Nacional sobre Drogas, Ministerio de Sanidad y Política Social (PND 0080/2011), the Agència de Salut Pública de Barcelona and the Departament de Salut. Government of Catalonia. Spain

Switzerland, Bern/Zürich: The IASP in Switzerland was funded by the Swiss Foundation of Alcohol Research (Grant # 209).

Hungary, Budapest: There was no direct funding, but the following grant was used: The European Union and the European Social Fund have provided financial support to the project under the grant agreement no. TÁMOP 4.2.1./B-09/1/KMR-2010-0003.

Australia: The IASP Screening Phase was funded by a strategic funding faculty grant from the Curtin University of Technology, Perth, Western Australia.

USA, Syracuse: no funding was obtained.

**Conflict of interest statements**

For coordination of the IASP study, as described in the funding resources part of this thesis, grants were received from pharmaceutical companies (Shire, Eli Lilly & company, Jansen Cilag), from participating institutes and from three not for profit organizations: the Waterloo Foundation, the Noaber Foundation and the Augeo Foundation.

The funding companies, institutes and foundations did not have and will not have influence on any aspect of the study, including research questions, data sampling, data management, data analyses and publishing results. Since September 2010 the IASP study, and the ICASA Foundation function independent from pharmaceutical companies.
G. Van de Glind was on one occasion consultant for Shire, for which he refused payment. In 2013 he received an unrestricted travel grant from Neurotech and he is (unpaid) member of the advisory board of Neurotech.
P-J. Carpentier received in 2011 fee for speaking at a conference organized by Eli Lilly.
F.R. Levin reports Study Medication provided by US World Meds; Consultant to GW Pharmaceuticals. The ICASA Foundation has reimbursed her for airfare to attend the Annual Meeting as a speaker.
S. Kaye reports receiving unrestricted travel grants for participation in the World ADHD Federation conference in Berlin (2011) from Shire, Janssen and Eli Lilly.
In the past year, S.V. Faraone received consulting income and/or research support from Shire, Akili Interactive Labs, VAYA Pharma, SynapDx and Alcobra and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. He receives royalties from books published by Guilford Press: *Straight Talk about Your Child’s Mental Health* and Oxford University Press: *Schizophrenia: The Facts.*
J.A. Ramos-Quiroga was on the speakers’ bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis, Shire and Rubió in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Shire, and Eli-Lilly. The ADHD Program chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Eli-Lilly, Janssen-Cilag, Shire, and Rubió.
M. Casas was on the speakers’ bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag and Shire in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Shire, and Eli-Lilly.
Z. Demetrovics received reimbursement for participating at a symposia organized by Lundbeck (2011).
G. Dom acted as a paid consultant for Lundbeck and received speakers fee and reimbursement for symposium attendance from GSK, Janssen Ph., Astra-Zeneca, Eli Lilly.
F. Moggi received speaker’s fee from Novartis and from Eli Lilly.
M. Auriacombe and his institution report unrestricted grants and advisory board activities from RBK Pharmaceutical, Mundipharma, D&A Pharma;
J. Franck declares his research group received an unrestricted research grant from Jansen-Cilag in 2007. The grant was received and administered by his university (Karolinska Institutet).
L. Degenhardt is supported by an Australian National Health and Medical Research Council (NHMRC) Principal Research Fellowship. The National Drug and Alcohol Research Centre at the University of NSW is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund.
W. van den Brink has received a fee from Eli Lilly for organizing a symposium on the role of impulsivity in psychiatric disorders and a speaker’s fee from Eli Lilly for a presentation on the relationship between ADHD and addiction.

The above mentioned authors and the other authors declare, apart from the funding resources mentioned in the 'Funding resources' paragraph, and the conflict of interests reported above, no other conflicts of interest.